藥明生物(02269.HK)盈喜:年度公司利潤增長105%以上
格隆匯2月7日丨藥明生物(02269.HK)發佈公吿,集團預期截至2021年12月31日止年度所錄得的公司利潤及歸屬於公司權益股東的利潤相比於去年同期分別增長105%以上及98%以上。
公吿稱,該增長主要是由於(其中包括)以下因素:(i)集團加速高效推進執行現存及新引進的COVID-19項目,支持並賦能全球客户抗疫並相應提升收益;(ii)憑藉領先的技術平台、行業最佳的項目交付時間及優秀的項目執行過往記錄,集團新的非新冠綜合項目收益和市場份額顯著增加;(iii)成功執行“贏得藥物分子”戰略,從而在研發管線中引入更多後期項目並提高近期收益;(iv)作為集團商業化生產元年,2021年相應生產項目收入大幅增長;及(v)2020年第一季度受疫情影響而短暫降低的生產效率已經完全恢復,加上現有產能和資源利用率的持續提升、以及運營效率改善項目的執行提高毛利率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.